NASDAQ$CLDX
Celldex Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results with a net loss for the first quarter of 2024.
Celldex Therapeutics reported its Q1 2024 financial results, with a revenue of $0.2 million and a net loss of $32.8 million. The company's cash position is strong at $823.8 million, expected to fund operations through 2027.
- Cash, cash equivalents and marketable securities totaled $823.8 million as of March 31, 2024.
- Total revenue was $0.2 million in the first quarter of 2024.
- Research and development expenses were $31.7 million in the first quarter of 2024.
- Net loss was $32.8 million, or ($0.56) per share, for the first quarter of 2024.
Headline financials
Revenue & EPS history
Celldex · Revenue · Quarterly
$156K
Forward guidance
Celldex believes that the cash, cash equivalents and marketable securities at March 31, 2024 are sufficient to meet estimated working capital requirements and fund current planned operations through 2027.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+1.3%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+1.7%
Avg return
30 days after
59%
38 / 64 earnings
Positive
+35.2%
Q4 2023
Best reaction
-21.5%
Q3 2014
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.2% | -7.0% | -16.8% | |
| Q4 2025 | -0.6% | -6.1% | -1.7% | |
| Q3 2025 | +7.6% | +12.7% | +23.2% | |
| Q1 2025 | +2.2% | -0.4% | -0.5% | |
| Q4 2024 | -1.6% | -3.1% | -3.4% | |
| Q3 2024 | +4.1% | +3.1% | +5.3% | |
| Q2 2024 | +2.7% | +3.8% | +36.5% | |
| Q1 2024 | -0.8% | -6.2% | -22.4% | |
| Q4 2023 | +35.2% | +37.4% | +10.7% | |
| Q3 2023 | +10.2% | +23.1% | +35.9% | |
| Q2 2023 | -6.5% | -7.4% | -13.3% | |
| Q1 2023 | +5.8% | +5.3% | +5.5% | |
| Q4 2022 | +7.9% | +8.7% | -17.4% | |
| Q3 2022 | +9.4% | +5.6% | +7.5% | |
| Q2 2022 | -3.8% | +1.7% | -17.7% | |
| Q1 2022 | -10.3% | -10.6% | -23.4% | |
| Q4 2021 | +4.7% | +0.5% | +14.7% | |
| Q3 2021 | +0.6% | -7.6% | -18.1% | |
| Q2 2021 | +6.2% | +3.7% | +20.9% | |
| Q1 2021 | -1.3% | -3.3% | +0.8% | |
| Q4 2020 | -16.9% | -4.0% | +30.4% | |
| Q3 2020 | +1.4% | +9.6% | +10.3% | |
| Q2 2020 | -3.5% | -12.3% | -7.5% | |
| Q1 2020 | +0.4% | +0.4% | +29.4% | |
| Q4 2019 | +3.4% | -7.3% | +68.2% | |
| Q3 2019 | -2.5% | -5.0% | -7.9% | |
| Q2 2019 | +6.2% | +1.4% | +2.9% | |
| Q1 2019 | -6.6% | -15.4% | -36.1% | |
| Q4 2018 | +9.0% | +4.3% | -7.3% | |
| Q3 2018 | +15.2% | +3.0% | -21.2% | |
| Q2 2018 | +0.0% | -6.7% | +2.2% | |
| Q1 2018 | -5.2% | -7.8% | -15.6% | |
| Q4 2017 | +14.1% | +17.0% | -17.4% | |
| Q3 2017 | +15.5% | +14.7% | +23.1% | |
| Q2 2017 | +2.4% | -0.8% | +11.7% | |
| Q1 2017 | +0.7% | +2.9% | -23.5% | |
| Q4 2016 | +1.8% | +2.1% | -2.1% | |
| Q3 2016 | +22.3% | +39.8% | +21.7% | |
| Q2 2016 | +0.4% | -4.3% | -21.5% | |
| Q1 2016 | -8.9% | — | — | |
| Q4 2015 | +10.9% | — | — | |
| Q3 2015 | +5.4% | — | — | |
| Q2 2015 | -21.4% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | +0.9% | — | — | |
| Q3 2014 | -21.5% | — | — | |
| Q2 2014 | +4.0% | — | — | |
| Q1 2014 | -3.3% | — | — | |
| Q4 2013 | -5.2% | — | — | |
| Q3 2013 | +4.2% | — | — | |
| Q2 2013 | -6.7% | — | — | |
| Q1 2013 | +2.5% | — | — | |
| Q4 2012 | +13.3% | — | — | |
| Q3 2012 | +5.9% | — | — | |
| Q2 2012 | -2.6% | — | — | |
| Q1 2012 | +1.5% | — | — | |
| Q4 2011 | +2.6% | — | — | |
| Q3 2011 | -3.6% | — | — | |
| Q2 2011 | -15.9% | — | — | |
| Q1 2011 | +0.5% | — | — | |
| Q4 2010 | -5.4% | — | — | |
| Q3 2010 | +7.6% | — | — | |
| Q2 2010 | -3.9% | — | — | |
| Q1 2010 | -2.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro